A 2 Week Blinded Study For Pain Due To Arthritis Of The Knee
NCT ID: NCT00483977
Last Updated: 2011-04-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2
113 participants
INTERVENTIONAL
2007-06-30
2007-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Oxycodone
Oxycodone
Oxycodone: oral controlled release, 20 mg, twice a day for 2 weeks
Placebo
Placebo
Placebo: oral for 2 weeks.
PF-00592379
PF-000592379
PF-00592379: oral, 30 mg, once a day for 2 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Oxycodone
Oxycodone: oral controlled release, 20 mg, twice a day for 2 weeks
Placebo
Placebo: oral for 2 weeks.
PF-000592379
PF-00592379: oral, 30 mg, once a day for 2 weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Between the ages of 18 and 75 years
* Knee Pain due to osteoarthritis
Exclusion Criteria
* Participation in a clinical trial for an investigational drug and/or agent within 30 days prior to baseline
* History of malignancy, convulsions, chronic infections, arthroscopy of the worst knee within the past year
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Pfizer, Inc.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Investigational Site
Mobile, Alabama, United States
Pfizer Investigational Site
Tucson, Arizona, United States
Pfizer Investigational Site
Carmichael, California, United States
Pfizer Investigational Site
Fair Oaks, California, United States
Pfizer Investigational Site
Orangevale, California, United States
Pfizer Investigational Site
Roseville, California, United States
Pfizer Investigational Site
Sacramento, California, United States
Pfizer Investigational Site
Boca Raton, Florida, United States
Pfizer Investigational Site
DeLand, Florida, United States
Pfizer Investigational Site
Hollywood, Florida, United States
Pfizer Investigational Site
Longwood, Florida, United States
Pfizer Investigational Site
Miami, Florida, United States
Pfizer Investigational Site
Louisville, Kentucky, United States
Pfizer Investigational Site
Madisonville, Kentucky, United States
Pfizer Investigational Site
St Louis, Missouri, United States
Pfizer Investigational Site
Las Vegas, Nevada, United States
Pfizer Investigational Site
New York, New York, United States
Pfizer Investigational Site
Durham, North Carolina, United States
Pfizer Investigational Site
Cincinnati, Ohio, United States
Pfizer Investigational Site
Cincinnati, Ohio, United States
Pfizer Investigational Site
Richmond, Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A7771010
Identifier Type: -
Identifier Source: org_study_id